May 01, 2020

#47 Sequences & Sparks: Life Sciences Innovation Mergers

Recent economic research has examined potential killer acquisitions in the U.S., and regulators here and abroad have expressed competition concerns about acquisitions of startups. But innovation is a difficult and uncertain process. This panel explores hot topics, patent thickets, biologics, and the revamped UK CMA approach in a broader discussion of the renaissance of innovation theories of harm.

Listen to the episode

Session Chair / Moderator / Speaker

E. Bill BATCHELOR / Skadden Arps Slate Meagher & Flom LLP, Brussels


  • Deborah Feinstein / Arnold & Porter, Washington, DC
  • W. Robert Majure / Cornerstone Research, Washington, DC
  • James R. Weiss / Deputy Assistant Director, Mergers I, Federal Trade Commission, Washington, DC

Presented by the Health Care & Pharmaceuticals Committee